Cantor Fitzgerald’s Outlook Therapeutics OTLK Stock Holding History

Cantor Fitzgerald’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Buy	+225,000	New	+$140K	﹤0.01%	297

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Cantor Fitzgerald's OTLK Position: Q2 2026 in Review

Cantor Fitzgerald opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 225,000 shares worth $358K. The stake represents ﹤0.01% of the portfolio and ranks #297 among its holdings.

69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Cantor Fitzgerald held 225,000 shares of Outlook Therapeutics worth $358K as of Q2 2026.
Outlook Therapeutics was a new Cantor Fitzgerald position in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #297 holding.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.